Posted by AGORACOM
at 2:27 PM on Thursday, January 14th, 2021
SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California
Here are four resolutions for conscientious local cannabis consumers to consider.
By all accounts, the Bay Area cannabis industry did remarkably well for itself in 2020.
Forced to deal with new COVID-19 restrictions, a crumbling economy, fallout from multiple wildfires, and a string of high-profile robberies, cannabis companies still managed to rake in close to $1 billion for California in state tax revenue alone.
At the same time, the window for equity brands to establish a viable foothold in the industry continues to rapidly close.
It’s now been a full three years since California’s adult-use market began in earnest. That’s a lot of time for consumers to develop brand loyalty, be it on the product side or the shops they frequent. Nonetheless, the time required to move through San Francisco’s equity program means that a number of new, equity-owned businesses are just now getting off the ground.
And they could use your help. In fact, there’s a number of ways individuals can make a difference! On that note — and in the spirit of starting 2021 on the right foot — here are four resolutions for conscientious local cannabis consumers to consider.
Shop Equity-Owned
There are two types of dispensaries that exist in San Francisco: those that were grandfathered in from the Prop. 215 days and those owned by equity operators. To be sure, there are plenty of great pot shops that fall into the former category, but in the spirit of spreading the love around, it’s also extremely important to support the new crop of Black and brown-owned dispensaries now open in the city if we hope to see them endure. In 2020 alone, new shops to open from equity owners include Stiiizy-Union Square (SF’s first dispensary owned by a Latina woman) and Posh Green (SFs first dispensary owned by a Black woman). There is also a newly created “SF Equity” seal that customers can look for when shopping for local products across all categories. More new shops, including one affiliated with the combo print shop and arcade, Free Gold Watch, are expected to open in 2021 as well.
Tour a Legal Grow
It may sound like a flowery platitude, but to truly understand cannabis, one should really see it grow. In the past, such a visit might have put you at risk of doing time, but nowadays, there are legal opportunities for individuals or groups to tour outdoor and indoor grow sites. Walking between rows of towering plants at the peak of harvest is something everyone should experience. From the scents to the scale to the solace, there is so much to soak in at a cannabis farm. As an added bonus, you’ll likely also get to meet the farmers responsible for growing your medicine. They can tell you about the ways smoke changes sunlight, which in turn affects terpene output. They can share their personal stories of what led them to this career (hint: when it comes to craft growers, the answer is not “getting rich”)
Cook with Cannabis
If we haven’t yet arrived at the molecular gastronomy phase of the cannabis cooking revolution, it’s assuredly coming soon. From the golden days of brownies baked by intuition, the modern edibles market is, by contrast, a brain-bursting cornucopia of choice and potential confusion. If you’re tired of trying to understand the difference between live resin and raw flower or continue to question how dosing works, why not get a little hands-on experience? The time has quite honestly never been better to bring cannabis into your home kitchen. Local cannabis chef (and Mellows founder) Stephanie Hua has a cookbook to guide newbies along, while San Francisco’s Potli prides itself on offering products designed to serve as staples of a cannabis-friendly pantry. Once you’ve tackled a few recipes on your own, you’ll likely have a far more nuanced appreciation for all of the many ingredients that go into preparing an infused edible!
Support Pot Non-Profits
Yes, 2020 was a big year for people asking for money. No, that’s not likely to end anytime soon. Of the many worthy causes in need of your funds, several groups focused on advocacy and racial justice within the legalized cannabis space are notably also seeking donations. In the Bay Area, Oakland’s the Hood Incubator is calling for financial contributions. It’s difficult to overstate how the industry — both in the Bay Area as well as across California — might look without their tireless efforts to empower local equity applicants to reach the finish line and remain viable. Another one to consider is the California chapter of the National Organization for the Reform of Marijuana Laws (NORML). Advocates for patients and sensible drug laws, it’s likely both CA NORML as well as the organization’s national wing will both be very busy this year as the prospect of federal decriminalization (or outright legalization) continues to gain traction in Congress.
Posted by AGORACOM
at 1:46 PM on Wednesday, January 13th, 2021
Matt Hawkins, Chairman of Harborside, will participate at the ATB 9th Annual Institutional Investor Conference, January 14, 2021
Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, announced that Matt Hawkins, Chairman of Harborside, will participate at the ATB 9th Annual Institutional Investor Conference, being held on January 14, 2021. Mr. Hawkins is scheduled to participate in a panel discussion, “U.S. Retail: What Leadership Looks Like Today and Tomorrow”, at 9:40am ET as well as host one-on-one investor meetings throughout the day.
About Harborside: Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and a cultivation/production facility in Salinas, California. Harborside has played an instrumental role in making cannabis safe and accessible to a broad and diverse community of California consumers. In 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States and today holds cannabis licenses for retail, distribution, cultivation, nursery and manufacturing. Harborside is currently a publicly listed company on the CSE trading under the ticker symbol “HBOR”. Additional information regarding Harborside is available under Harborside’s SEDAR profile at www.sedar.com.
Posted by AGORACOM
at 8:48 AM on Monday, December 21st, 2020
Expands Footprint with Social Equity Dispensary in Historic Haight-Ashbury District
Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, announces the closing of the transactions contemplated by the previously announced agreement to acquire 50.1% of the equity (the “Shares”) of FGW Haight, Inc. (“FGW”), a California corporation which has the conditional use approval necessary to operate a cannabis dispensary and related businesses in the Haight Ashbury area of San Francisco, California (the “Acquisition”).
With the completion of the Acquisition, Harborside expands its retail dispensary footprint in the state of California to five and solidifies a strong presence in the historic and culturally-significant Haight-Ashbury district of San Francisco. The Company expects to complete the build-out, receive all necessary regulatory approvals, and open the social equity retail dispensary in the third quarter of 2021.
“I’m excited to continue to expand our footprint in California and look forward to serving consumers in Haight Ashbury,” said Peter Bilodeau, Interim CEO of Harborside. “Together, we will work with the team from FGW to give back to the community and support initiatives to address the negative impact of past cannabis policies which have disproportionally impacted low income and minority community members. This new location will also introduce the best-in-class service and unbeatable product selection that Harborside has become famous for to an iconic area of San Francisco.”
Upon closing of the Acquisition, Harborside paid an aggregate purchase price of USD $2,179,350 based on a post-build-out and proforma working capital enterprise value of USD $4,350,000 (the “Purchase Price”). The Purchase Price is comprised of: (a) USD $1,265,000 as consideration for convertible notes of FGW entitling the Company to such number of underlying Shares equal to 29.1% of the Shares; and (b) the balance of the Purchase Price in multiple voting shares (“MVS”) valued at CAD$125 per MVS as consideration to certain selling shareholders of FGW for 21% of the issued and outstanding Shares.
Subject to regulatory approval, Harborside has also agreed to purchase an additional 29.9% of the issued and outstanding Shares (the “Subsequent Shares”) to get to an 80% ownership of FGW, subject to regulatory approvals. The aggregate purchase price for the Subsequent Shares will be USD $1,300,650, which will be satisfied in MVS valued at the greater of: (i) the 30 day VWAP of the subordinate voting shares of the Company on the Canadian Securities Exchange (“CSE”) at the time of issuance less a discount multiplied by 100; (ii) CAD$150 per MVS; or (iii) such other price as may be approved by the CSE. Harborside also retains the right of first refusal to purchase, in its discretion, in whole or in part and in one or more closings, the remaining 20% of the Shares, subject to regulatory approvals.
About Harborside: Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and a cultivation/production facility in Salinas, California. Harborside has played an instrumental role in making cannabis safe and accessible to a broad and diverse community of California consumers. In 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States and today holds cannabis licenses for retail, distribution, cultivation, nursery and manufacturing. Harborside is currently a publicly listed company on the CSE trading under the ticker symbol “HBOR”. Additional information regarding Harborside is available under Harborside’s SEDAR profile at www.sedar.com.
Posted by AGORACOM
at 11:04 AM on Wednesday, December 16th, 2020
SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California
Purchasers of Marijuana Pay About 10 Percent in State Taxes on Retail Buys
The sale of cannabis in California went legal in 2016, and retailers were able to open their doors two years later. Along with the legal retail sale of cannabis came two new taxes — a cultivation tax on all harvests and an excise tax on the purchase of weed and products made with it; the usual sales taxes, both state and local, also applied. They add up, and in the third quarter of 2020, California’s total cannabis tax revenue was $306.7 million. Of that amount, the state gained sales and excise tax on $11 million worth of retail cannabis sold in cities in Santa Barbara County.
For $30 worth of cannabis flower, or buds, the taxes can raise the consumer’s payment to $41.77, the state Tax and Fee Administration (CDTFA) calculated. That includes a 15 percent excise tax and the state’s 8.5 percent sales tax. The CDTFA also added a 10 percent cannabis business tax, which is charged by most California jurisdictions, although Santa Barbara County’s cities’ rate is 5-6 percent. The cultivation tax is paid by weight when the farmer sells to a distributor.
The breakdown of the $306 million in taxes are excise tax of $159.8 million, cultivation tax of $41 million, and sales tax of $105.9 million. For the previous year’s July to September, the cannabis taxes to the state were $170.8 million.
The previous quarter, or April through June, generated $260 million for the state, and the first quarter of January to March generated close to $206 million. Santa Barbara County’s retail cannabis sales saw a similar move upward from the first to second quarter, the Tax and Fee Administration reported. January to March sales were $9 million, and April to May sales were $16.7 million. Many speculate the increase is due to the shutdown.
Santa Barbara County has yet to permit any retail cannabis stores and is in the process of determining where eight will go in the county’s unincorporated areas. If the $11 million in sales would have occurred in county areas, the income would have been about $441,000 with the county’s 4 percent retail cannabis tax, said Jeff Frapwell of the County Executive Office.
Correction: Santa Barbara County plans eight retail cannabis stores, not six; and this story has been updated to reflect local business tax amounts.
Posted by AGORACOM
at 9:37 AM on Tuesday, December 8th, 2020
SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California
SAN DIEGO — On Friday the United States House of Representatives passed a bill decriminalizing marijuana at the federal level. Although it is unlikely to pass the Senate, it has industry leaders here in California excited that the conversation towards decriminalization is rolling in Washington.
After receiving some rare bi-partisan support, the Marijuana Opportunity Reinvestment and Expungement or MORE Act passed the House of Representatives by a large margin. Highlights of the bill include:
Decriminalizing marijuana federally
Establishing a 5% federal tax on all cannabis products
Prohibiting the denial of federal benefits to people convicted of cannabis-related crimes
The bill would start the process of expunging the records of those convicted of Cannabis-related offensives
Will Senn is the founder of Urbn Leaf, a marijuana dispensary in San Diego. He says that the bill has been a long time coming and that it was a historic win for the industry. He went on to say that attitudes towards marijuana are shifting around the country. “I think the writing is on the wall, right? Everybody is voting for cannabis legislation nationwide. You had five more states pass some legislation in the last election year. There’s a number of upcoming bills in the near future here.”
Marijuana has been decriminalized in California since 1996 but attitudes about the plant differ drastically around the country. According to the FBI and the Pew Research Center, in 2018 40% of the 1.65 million drug arrests from around the country were marijuana-related and 92% of them were for possession.
Jason Ortiz from the Minority Cannabis Business Association said, “So, I mean, there are thousands at the very minimum, especially on the federal level. But as you start to extend the impact statewide, it could be upwards of millions of records that would get affected.”
Ortiz added that the potential expungement of cannabis-related crimes off a person’s record could change the lives of thousands of people, “And having that on your record denies you access to housing, to jobs, to other sorts of social services.”
Although the bill passed in the House, it’s unlikely that it will see a vote in the Senate. Still, business owners like Senn see it as an important benchmark of just how far the conversation around decriminalizing marijuana has come since he entered the industry.
Posted by AGORACOM
at 1:03 PM on Thursday, December 3rd, 2020
SPONSOR: Harborside is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments, Retail Dispensaries, Cultivation and Processing and Wholesale Sales (including branded product sales). Harborside operates the only drive through dispensary in California
This week the U.S. House of Representatives is expected to vote on a bill that would remove marijuana from the Controlled Substances Act and require federal courts to expunge many prior marijuana offenses. It will be the first time the full House will vote on ending the federal prohibition of cannabis.
Morgan Fox with the National Cannabis Industry Association says House passage would “send a really strong message to not only the rest of Congress, but to a lot of other states that the time to end prohibition has come.”
The Marijuana Opportunity Reinvestment and Expungement Act (MORE Act), introduced by Rep. Jerry Nadler (D., N.Y.), would eliminate conflict between state and federal law and allow states to set their own marijuana policies.
“We don’t need to have one size fits all. We just need to get rid of prohibition and then let the states do what the states are doing. It’s essentially what the states have done already. They haven’t waited for the federal government, which is why we have a lot of these discrepancies and challenges,” said Rep. Earl Blumenauer (D., Ore.), who has long pushed for marijuana legalization.
Blumenauer and Rep. Barbara Lee (D., Calif.) — who also wrote parts of the legislation — told Yahoo Finance the bill is a racial justice issue.
“It’s coming at a time when Americans are recognizing how hopelessly flawed the criminal justice system is,” said Blumenauer.
‘You’ve got to repair the damage’
The MORE Act would impose a 5% sales tax on marijuana and marijuana products. The revenue would go toward a new trust fund for grant programs designed to help people “adversely impacted by the War on Drugs” access job training, re-entry services, legal aid, treatment and more. The bill would also provide protections prohibiting denial of federal benefits based on use, possession or conviction for a marijuana offense.
“Regardless of who you are, if you’ve been incarcerated and if you’ve done your time and you get out, you should be provided for a second chance,” Lee told Yahoo Finance. “When you’ve been incarcerated or when you have have a record based on unjust laws — they’re really targeted in many ways, Black and Brown people — then you’ve got to make restitution, you’ve got to repair the damage. This fund is about the time that was lost because of barriers to employment, because of incarceration.”
The MORE Act would open up more opportunities for marijuana businesses, including access to Small Business Administration funding. It would also require the Bureau of Labor Statistics to gather demographic data on cannabis business owners and employees to ensure people of color and economically disadvantaged people are taking part in the industry.
“That really sets out a process for equity in the industry. This is a job-creating industry, and it also provides economic opportunities for minority-owned business owners,” said Lee.Graphic by David Foster/Yahoo Finance
The House Judiciary Committee passed the MORE Act last year 24 to 10 — Rep. Matt Gaetz (R., Fla.) and Rep. Tom McClintock (R., Calif.) were the only Republicans who voted for the bill.
In an interview with Yahoo Finance, McClintock said while he didn’t endorse marijuana, it’s clear U.S. marijuana laws have “not accomplished their goals.”
“These laws have done far more harm than good. They’ve created a violent underground economy and ruined the lives of so many young people who’ve had a youthful marijuana conviction, follow them and ruin their lives,” said McClintock.
The House was scheduled to vote on the bill in September, but Democratic leadership postponed the vote because some members in tight races worried passing the MORE Act before a stimulus package could hurt them at the polls.
Nearly a month after the election, there is still no additional coronavirus relief and many Republicans are again slamming Democrats for what they see as prioritizing the cannabis bill over coronavirus relief efforts.
Democrats have already passed two versions of the Heroes Act and argue it’s the Trump administration and Republican Senate that’s holding up stimulus talks.
Posted by AGORACOM
at 6:09 PM on Wednesday, November 25th, 2020
OAKLAND, Calif. and TORONTO, Nov. 25, 2020 /CNW/ – Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, announced today that the nominees set forth in the Company’s Management Information Circular dated October 26, 2020, Mr. Matthew Hawkins, Mr. Kevin Albert, Mr. Michael Dacks, Mr. Peter Kampian, Mr. Alexander Norman, Mr. James Scott, and Mr. Andrew Sturner, were elected as directors of the Company at the annual meeting of shareholders held today (the “Meeting”). At the Meeting, shareholders also approved the re-appointment of MNP LLP as the auditor of the Company, Harborside’s Equity Incentive Plan, and a special resolution approving certain housekeeping amendments to the articles of the Corporation.
“On behalf of the entire Board, I’d like to thank our shareholders for their overwhelming support and for placing their trust in us to lead Harborside through its next phase of growth,” said Matthew K. Hawkins, Chairman of Harborside. “With a strengthened leadership team in place, we will work together to leverage our high-quality products and brands to accelerate our momentum and drive strong shareholder value. I look forward to updating you as we execute on the opportunity ahead.”
Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and a cultivation/production facility in Salinas, California. Harborside has played an instrumental role in making cannabis safe and accessible to a broad and diverse community of California consumers. Co-founded by Steve DeAngelo and dress wedding in 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States and today holds cannabis licenses for retail, distribution, cu
ltivation, nursery and manufacturing. Harborside is currently a publicly listed company on the CSE trading under the ticker symbol “HBOR”. Additional information regarding Harborside is available under Harborside’s SEDAR profile atwww.sedar.com.
Posted by AGORACOM
at 12:54 PM on Wednesday, November 25th, 2020
Harborside Inc (CSE: HBOR) is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments that generated record gross revenue in the 3rd quarter 2020.
Harborside operates the only drive through dispensary in California and is one of the oldest and most respected cannabis retailers in California:
Operations have generated over $400M in cumulative sales since inception
Generated 21.2% Sequential Revenue Growth Q3
Record Gross Revenues of $19.6 Million
Expects Full Year Gross Revenues of Approximately $61 Million – $63 Million from 5 dispensaries
OPERATIONS:
California Focused
Harborside dispensaries have generated over $400M in sales to date, and are strategically focused on growing market share in California.
The SF Bay Area cannabis market is expected to grow from ~$667M in 2018 to ~$1.5B in 20221
Market potential & growth for California eclipses the combined value of FL, NY, MA & NV
RETAIL OPERATIONS
Harborside dispensaries are preeminent NorCal cannabis retail operations with a significant track record and expertise gained through 13 years of operations.
Retail operations command 3% of California’s entire retail market
Harborside operates five dispensaries that are expected to produce approximately $62M in sales in 2020.
Significant market share and captive shelf space drive industry-leading sales
Recently opened two new Harborside locations to further expand California footprint
Watch the Video to see how Harborside works:
Harborside is an advertising client of AGORA Internet Relations Corp.
Posted by AGORACOM-JC
at 11:10 AM on Monday, November 23rd, 2020
Despite the collapse of marijuana and cannabis related stocks in the last 18 months, there is no denying that Cannabis related products are going to go through a paradigm shifting, parabolic growth stage around the world over this decade for the following reasons:
1. Cannabis legalization is gaining momentum around the world.
2. Momentum is primarily driven by the realization that cannabis may have a range of medicinal, therapeutic and wellness applications.
3. It is the most widely cultivated, consumed and trafficked drug worldwide (United Nations Office on Drugs and Crime).
So what is this going to translate into?
The global cannabis market size was valued at $US 10.6 Billion in 2018 and is projected to reach $97.5 Billion by the end of 2026, a CAGR of 32.92%(Fortune Business Insights)
WHY WILL THIS TIME BE DIFFERENT?
Big promises, big IR budgets, big hype …. Big Letdown.
That pretty much sums up the last cycle of Cannabis related companies that focused on speed, stories and stock prices rather than the one simple but important thing they should have been doing – building a real business.
Investors will remember that the same thing happened during the dot-com era. As with the cannabis collapse over the last 18 months, what followed back in 2000 was a long period of mourning in which many investors had sworn off tech stocks, just as they have with cannabis stocks today.
But it wasn’t long until tech investors dusted themselves off and realized tech was here to stay – but this time they were only going to focus on real companies with real businesses. What we got was Amazon, Google, Linkedin, Facebook and then the rest was history.
US LEGALIZATION IS ACCELERATING
After postponing a proposed September vote, the full U.S. House of Representatives is expected to vote in December on a bill that would effectively legalize marijuana federally by removing it from the Controlled Substances Act.
According to Politico, the House Democratic leadership is preparing for a vote on the Marijuana Opportunity Reinvestment and Expungement (MORE) Act of 2019. In addition to legalizing marijuana federally, the legislation would allow states to continue to choose how to regulate a commercial MJ industry.
Democrats in close elections balked at voting on the MORE Act in September amid concerns that voters might question the importance of legalizing marijuana when Congress had failed to agree on a coronavirus aid package.
But in the November election, five more states legalized medical and/or recreational marijuana, and a recent poll shows cannabis legalization is more popular than ever.
Big cap marijuana stocks have already seen significant gains
Meet the 8 new small cap marijuana horsemen of the next leadership group that are firing on all cylinders (in alphabetical order).
Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.
When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:
1. The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year. These are the only known CBD cosmetics backed by clinical trials.
2. Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.
3. Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.
For more information about the company, please check out the Avicanna HUB on AGORACOM.
Harborside (HBOR: CSE), (HSDEF: OTCQX) has generated over $400,000,000 (NOT a typo) since its inception in 2006. We thought that would get your attention.
What Do They Do?
HBOR is a California-focused, vertically integrated, fully licensed cannabis company with its business consisting of three primary segments:
1. Retail Dispensaries
2. Wholesale
3. Cultivation and Processing
HIGHLIGHTS
Founded in 2006. One of the oldest and most respected cannabis retailers in California
Awarded one of the first six medical cannabis licenses in the USA
Operations have generated over $400M in cumulative sales since inception
Retail operations command 3% of California’s entire retail market
Q3 REVENUE ($USD)
· $19.6M +43% vs. Q3 2019
9 MONTHS ENDED SEPT. 30, 2020
· $50.4M + 33% vs 2019
OTHER Q3 HIGHLIGHTS
21.2% Sequential Revenue Growth, with Record Gross Revenues and Continued Positive Adjusted EBITDA of $4.5 million
Strong Combined Gross Margin of 54.7% (1) Driven by Improved Harvest Yields and Higher Wholesale Volumes
Expects Full Year Gross Revenues of Approximately $61 Million – $63 Million with Adjusted EBITDA of 8-10%
For more information about the company, please check out the Harborside Inc hub on AGORACOM.
Hollister Biosciences Inc. (HOLL:CSE) (HSTRF:OTC) (HOB: FRANKFURT) is a multi-state cannabis company with products in 230 dispensaries throughout California and over 80 dispensaries throughout Arizona, translating into the following great success:
REVENUES $USD
Q1 +317% YoY to $862,000
Q2 +3685% YoY to $8,500,000
Q3 +5081% YoY to $12,500,000
TOTAL Q1/Q2/Q3
REVENUE $21.8M
With the recent passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona Hollister is extremely well positioned to capitalize. This can best be summed up by quote of Venom Extracts Founder below:
“Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024 1 , significantly expanding the total addressable market for Cannabis in the state. We look forward to making our product line available to both the medical and recreational end user.” Shared Jacob Cohen , Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona
On September 23rd, 2020, Venom achieved the first revenue milestone by generating in excess of CDN$30,000,000 of revenue calculated from January 1 st , 2020
In addition to organic sales, Hollister has several high-level partnerships that demonstrate how trusted the Company is within the industry, including:
For more information about the company, please check out the Hollister Biosciences Inc. hub on AGORACOM.
Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.
3 Fully Operating Divisions For Investor Diversification
Innocan has 3 fully operating divisions to address the market for Cannabis products. As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.
PHARMACEUTICAL – THE GUIDED MISSILE – Revolutionary technology targeting lungs infected with coronavirus or other viral infections.
CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.
OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.
Global Manufacturing / Distribution Agreements
Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)
Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)
Superior Management Team
In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself. The InnoCan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:
Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world
Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)
Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.
Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.
Together they have built one of the most formidable teams in the small cap cannabis world
For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.
Spyder Cannabis Inc. (SPDR :TSXV) is a Cannabis, Vape and CBD retailer with three retail business units.
SALE OF CANNABIS PRODUCTS – The Company has TWO cannabis dispensaries currently in operation. The first being a location in Calgary, Alberta and the second in Niagara Falls. Both dispensaries are located in busy commercial hubs. The management team is currently evaluating several additional locations in both Alberta and Ontario where it intends to expand the Spyder Cannabis brand’s footprint.
SALE OF HEMP CBD (US) Company is also pursuing the sale of Hemp based CBD products from locations in the USA.
SMOKING CESSATION PRODUCTS IN ONTARIO The company sells electronic cigarettes, E-juice and accessories for the “vape” business from five Canadian retail locations; Woodbridge, Scarborough, Pickering, Niagara Falls and Burlington, Ontario. Spyder has established itself as a savvy retailer.
For more information about the company, please check out the Spyder Cannabis hub on AGORACOM.
Thoughtful Brands, Inc. (TBI: CSE)( 1WZ1: FWB)( PEMTF: OTCQB) is a global natural health products and eCommerce technology company that is operating at full throttle.
Acquired eCommerce retailers with combined total sales of approximately $29,000,000 with an EBITDA of approximately 12.5%.
Current customer base of over 200,000 customers with additional leads of over 600,000 potential new customers
Enhanced eCommernce solution through Unified Funding’s software which facilitated over $350 million in consumer transactions (CAD $93.8 million) in 2019 from more than one million paying customers.
Low-cost production will be vertically integrated into retail brands to achieve up to 20x margin increase.
We’ll let these revenue numbers speak for themselves.
August 2020 CAD $3,809,000
July 2020 CAD $2,340,000
June 2020 CAD $2,712,000
The above represents an increase of 19%, over the same period in 2019.
QUARTERLY REVENUE $CAD
Q1 $7,600,000 Growth
Q2 $12,800,000 Growth
TOTAL Q1 AND Q2
REVENUE $20,400,000
GROSS PROFIT $2,154,357
The company has its sights set on European expansion through a joint venture with Franchise Cannabis Corp. The company will now sell and market Franchise-manufactured CBD, hemp and cosmetic products in the European Union, Switzerland, Norway and the UK, utilizing its eCommerce platform.
The company also completed acquisition of Verrian, which owns and operates a 110,000-square foot pharmaceutical manufacturing facility in Radebuel, Germany. This acquisition will assist the company in tapping into the burgeoning market for psychedelics as Verrian specializes in developing psychedelic derived medicines for treatments for addictions, including opioids and alcohol.
In Addition, the company entered into a definitive agreement to acquire American CBD Extraction Corp. and its Kentucky-based wholly owned subsidiary East Kentucky Extractions, LLC. the Company will gain access to an abundance of hemp biomass in Kentucky, and own a fully equipped and licensed 41,000 square foot facility that can process more than 1,200 pounds of hemp per day.
For more information about the company, please check out the Thoughtful Brands hub on AGORACOM.
TransCanna (TCAN:CSE) (TH8:FSE) owns a 196,000 square foot cannabis Facility, the largest known fully licensed cannabis facility in California.
CAD$24.9M Revenue Run Rate from 10,000 sq.ft test facility
CAD $90M Annual Revenue expected from first full year of production at Fully Licensed Daly Street Facility.
Acquired two California companies,
High-end award winning edible producer Soldaze
Premium indoor cultivator and distributer Lyfted Farms
Lyfted Farms products sold in select Cookies Locations – The most recognizable name in high-end Cannabis.
2019 California Cannabis sales over $3B, industry currently fragmented
Direct to dispensary model, cutting out the middleman
REVENUES $CAD
Q1 $906,000
Q2 $4,300,000
TOTAL Q1 AND Q2
REVENUE $5,206,000
GROSS MARGIN $1,920,000
OFF-TAKE AGREEMENTS
· The Company has secured multiple off-take agreements in anticipation of late Q1 production coming out of the Daly facility
REVENUE GUIDENCE
· Company’s internal gross revenue target for the 2020 fiscal year ranges from CAD$12,000,000 up to CAD$14,000,000 (with anticipated net profits from sales of $600,000 up to $700,000) On track to achieve this benchmark
Company maintains its guidance for a gross revenue target of CAD$55,000,000 to CAD$75,000,000 (with anticipated net profits from sales of $6,600,000 up to $9,000,000) for the fiscal year 2021.
This revenue guidance is only for phase one of four in the Daly facility
· For more information about the company, please check out the TransCanna hub on AGORACOM.
Thanks for reading and discovering these great small cap cannabis companies. Please be sure to visit the AGORACOM Small Cap Cannabis Gateway often to stay up to date with new companies at:
Posted by AGORACOM
at 8:18 AM on Wednesday, November 18th, 2020
Generates 21.2% Sequential Revenue Growth, with Record Gross Revenues of $19.6 Million and Continued Positive Adjusted EBITDA (1) of $4.5 million
Reports Strong Combined Gross Margin of 54.7% (1) Driven by Improved Harvest Yields and Higher Wholesale Volumes
Expects Full Year Gross Revenues of Approximately $61 Million – $63 Million with Adjusted EBITDA of 8-10% (1)(2)
OAKLAND, CA and TORONTO, Nov. 18, 2020 /CNW/ – Harborside Inc. (“Harborside” or the “Company”) (CSE: HBOR) (OCTQX: HBORF), a California-focused, vertically integrated cannabis enterprise, today reported its financial results for the period ending September 30, 2020 (“Q3 2020”). The Q3 2020 financial report and corresponding management’s discussion and analysis (collectively the “Q3 Filings”) are available for download from the Company’s investor website,investharborside.com, and on the Company’sSEDAR profile. Unless otherwise indicated, all dollar amounts in this press release are in U.S. dollars.
Management Commentary
“We’ve implemented strong operational improvements that have continued our progress towards long term profitability and sustained growth. Harborside continues to be one of the leaders in the Northern California market,” said Peter Bilodeau, Chairman, and interim Chief Executive Officer. “As our production capacity is expected to ramp up in early 2021, following the completion of the planned upgrades at our Salinas greenhouse facility, we expect to be well-positioned to accelerate our growth and continue to gain wholesale market share. I’m thrilled with how far Harborside has come this year and look forward to further growth in 2021.”(2)
Q3 2020 Financial Results and Highlights (2)(3)
Q3 2020
Q2 2020
Q1 2020
Q4 2019
Retail Revenues
$10,681,897
$10,940,143
$10,181,471
$9,511,221
Wholesale Revenues(a)
$8,890,723
$5,208,439
$4,456,775
$2,185,701
Total Gross Revenues(a)
$19,572,620
$16,148,582
$14,638,246
$11,696,922
Retail Gross Profit(e)
$5,353,429
$5,601,565
$5,219,890
$4,903,947
Wholesale Gross Profit(a)(e)
$5,360,764
$2,435,952
$787,964
-$1,373,186
Total Gross Profit(a)(e)
$10,714,193
$8,037,517
$6,007,854
$3,530,761
Retail Gross Margin(b)(e)
50.10%
51.20%
51.30%
51.60%
Wholesale Gross Margin(a)(e)
60.30%
46.80%
17.70%
-62.80%
Total Gross Margin(e)
54.70%
49.80%
41.00%
30.20%
G&A/Professional Fees(c)(d)
$6,783,987
$6,764,781
$5,786,573
$7,621,971
Adjusted EBITDA(e)
$4,473,046
$642,025
$431,562
-$2,796,178
NOTES:
a. Not including excise taxes or biological asset adjustments.
b. Retail gross margin in Q1 2020 and Q2 2020 are slightly affected by additional expenditures on personal protective equipment and other safety measures due to the COVID-19 pandemic. Retail gross margin in Q2 2020 and Q3 2020 include additional pay for the Company’s front line workers and expenses relating to the impacts of the civil unrest in the Bay Area to certain of the Company’s retail stores.
c. Professional Fees for the fourth quarter of 2019 include approximately $953,000 in one-time fees and accruals for legal matters
d. Professional Fees for Q2 2020 and Q3 2020 include approximately $977,000 and $1,115,000, respectively, in one-time costs relating to the audits and restatements of certain of the Company’s previous financial statements.
e. This is a non-IFRS reporting measure. For a reconciliation of this to the nearest IFRS measure, see “Use of Non-IFRS Measures” and “Non-IFRS Measures” in the Company’s management discussion and analysis for September 30, 2020.
Q3 2020 Financial Summary
During Q3 2020, Harborside generated total gross revenues of approximately $19.6 million. This represented 21.2% sequential growth over the second quarter of 2020 (“Q2 2020”) and a 42.9% year-over-year increase when compared to the approximately $13.7 million of gross revenues reported in the period ending September 30, 2019 (“Q3 2019”). Combined gross profit before excise taxes and adjustments for biological assets was approximately $10.7 million, an 85.8% year-over-year increase as compared to the $5.8 million reported in Q3 2019. On a year over year basis, combined gross margins increased from 42.1% in Q3 2019 to 54.7% in Q3 2020(1).
Harborside’s wholesale operations reported gross wholesale revenues of approximately $8.9 million, representing 70.7% sequential growth compared to Q2 2020 and a year-over-year increase of 169.4% as compared to the approximately $3.3 million in gross revenues reported for Q3 2019. The year-over-year increase in gross wholesale revenues was primarily due to improved harvest yields and production of premium flower, higher sales volumes, and higher average prices per pound at the Company’s 47-acre integrated production campus in Salinas, California (the “Salinas Facility”). As compared to gross wholesale revenues, wholesale gross margins increased from -22.1% in Q3 2019 to 60.3% in Q3 2020(1).
The Company’s retail operations generated revenues of approximately $10.7 million, a 2.8% increase as compared to the approximately $10.4 million realized in Q3 2019, with gross margins improving from 48.5% to 50.1% on a year-over-year basis, despite increased costs for safety and staffing related to COVID-19 and inventory losses experienced during the civil unrest that occurred in the Bay Area.(1) The year-over-year increase in retail revenue was driven primarily by the Company’s enhanced merchandising and pricing initiatives which resulted in, amongst other things, improved product mix, selected pricing changes and higher sell-through of internally produced products. Across Harborside’s retail stores in California, the Company’s branded products represented from 9 to 14 of the 25 top-selling SKUs in Q3 2020.
Total operating expenses for Q3 2020 were approximately $7.8 million, including $1.15 million in one-time costs related to the audit and restatement of prior year financials. This was a 7.5% year-over-year decrease when compared to approximately $8.5 million of costs incurred in Q3 2019. The year-over-year decrease in operating expenses is primarily related to a decrease in general and administrative expenses of $1.1 million to $4.1 million as compared to $5.2 million in Q3 2019, a decrease in allowance for credit losses of $0.3 million, and a decrease in write-downs of receivables, investments and advances of $1.3 million, as no impairments were recorded on any of the Company’s investments in Q3 2020.
During Q3 2020, the Company also recorded an income tax provision of $1.8 million, compared to $1.3 million in Q3 2019, based on estimated federal income taxes payable at period-end.
Operating Income for Q3 2020 was approximately $0.8 million, compared to an operating loss of approximately $3.6 million for Q3 2019. Net loss and comprehensive loss was $2.4 million, compared to a net loss and comprehensive loss of $1.9 million in Q3 2019, a 24.2% decrease on a year-over-year basis. The year over year decrease was due primarily to additional income tax provisions and related interest expense booked during Q3 2020.
Adjusted EBITDA(1) for Q3 2020 was approximately $4.5 million, compared to a negative EBITDA(1) of approximately $0.9 million for Q3 2019, with the year over year increase being driven largely by improved operating efficiencies and headcount reductions across the Company. See “Non-IFRS Financial Measures, Reconciliation, and Discussion.”
Q4 2020 and Full Year Expectations (2)(4)
The Company expects Q4 2020 gross revenues to follow a more historically typical seasonal pattern, with lower flower production and wholesale revenues, resulting in total combined gross revenues of $11 million to $12.5 million for the fourth quarter, with EBITDA(1) for the quarter close to breakeven. For the full year ended December 31, 2020, the Company expects gross revenues in the range of approximately $61 – $63 million, with Adjusted EBITDA(1) for the year in the range of 8 – 10% of revenues.
Liquidity and Cash Balance (2)(3)
As of September 30, 2020, Harborside had approximately $13.3 million in cash. The increase in cash balance since the second quarter of 2020 included a delay in payment of approximately $1.6 million of sales taxes that were due to the state of California. Payment of these taxes was postponed by the state as part of their COVID-19 business relief program and, in accordance with state guidelines, the funds were ultimately remitted at the end of October 2020.
Recent Operational Highlights
Wholesale Operations: Harborside recently announced planned cultivation facility upgrades at the Salinas Facility. The planned upgrades include, among other things, the installation of blackout curtains and supplemental LED grow lights at the Salinas Facility. Following the successful completion of these upgrades, the Company expects an approximately 50% increase in production, an expected approximately 10% increase in bulk wholesale revenue capacity, and an approximately 7% increase in the total productive capacity, on an annualized basis(2)(4). The upgrades are expected to be completed within the first quarter of 2021(2).
In furtherance of its brand strategies, Harborside announced that two of its award-winning in-house brands, Harborside Farms and Key, introduced new product offerings for the market. Key has added ‘Key Mini Pre-Rolls’, a pack of seven 0.5g strain specific pre-rolls, to its product suite. These mini pre-rolls use flower that is sustainably grown in Harborside’s state of the art greenhouses using proprietary techniques. Key also recently offered a new seasonal SKU, ‘Limited Edition Skeleton Key Mini Pre-Rolls’, a nighttime blend of G4 OG and Gelato 33 packed in seven 0.5g mini pre-rolls. Harborside Farms has also added ‘Harborside Farms Quarter Ounces’, which offers strain-specific and single-origin flower from Harborside Farms. The Company also recently commenced sales of clones grown at its Salinas Facility at all Harborside branded retail locations, including Desert Hot Springs.
Capital Markets: During Q3 2020, the Company commenced trading on the OTCQX under the ticker symbol of “HBORF” and, subsequent to the quarter end, Harborside received depository trade clearance (DTC) eligibility.
Acquisitions: Subsequent to Q3 2020, Harborside announced it had executed a definitive agreement with FGW Haight, Inc. (“FGW”) to acquire majority ownership FGW, which holds a dispensary license in the historic Haight-Ashbury District of San Francisco, where the Company expects to start operations in the second quarter of 2021(2).
Secured Indemnity
On November 17, 2020, the Company and its subsidiaries entered into a guaranty and security agreement to guarantee and secure the obligations of the Company to defend and to indemnify its directors and officers (collectively, the “Secured Indemnity“). The Secured Indemnity is intended to supplement coverage available under existing directors and officers insurance maintained by the Company in order to mitigate concerns about claims and potential claims against directors and officers and whether the available insurance applies to and will satisfy in full such claims and potential claims. The scale and complexity of the Company’s operations in a highly regulated sector requires that the directors and officers managing those operations be committed to the performance of their duties without undue or inappropriate distractions. In management’s view, concerns about claims and potential claims and adequacy of insurance may detract from the performance of the directors and officers involved in the Company’s operations or lead to their resignations, which would disrupt the Company’s business. The Board has therefore determined that it is in the best interests of the Company and its subsidiaries to enter into the Secured Indemnity in order to induce the directors and officers to perform their duties to the Company, provide comfort to the directors and officers involved in the Company’s operations and to encourage their ongoing services.
The Secured Indemnity constitutes a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions (“MI 61-101“). The Company is relying on the exemptions from the valuation and the minority approval requirements of MI 61-101 provided for in subsections 5.5(a) and 5.5 (b) and subsection 5.7(a) of MI 61-101, respectively, as the Company’s shares are not listed on specified markets and neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the Secured Indemnity, in relation to the interested parties, will represent more than 25% of the Company’s market capitalization, as determined in accordance with MI 61-101.
Harborside Inc., a vertically integrated enterprise with cannabis licenses covering retail, distribution, cultivation, nursery, and manufacturing, is one of the oldest and most respected cannabis companies in the world. Founded in California in 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States. Today, the company operates three major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and an integrated cultivation/production facility in Salinas, California. Harborside continues to play an instrumental role in making cannabis safe and accessible to a broad and diverse community of California and Oregon consumers. Harborside is currently a publicly listed company, trading on the CSE under the ticker symbol “HBOR” and the OTCQX under the ticker symbol “HBORF”. Additional information regarding Harborside is available under Harborside’s SEDAR profile atwww.sedar.com.
